Article Text
DTB Select
CVS effects of ▼ canagliflozin
Statistics from Altmetric.com
Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been reported to reduce macrovascular complications in people with type 2 diabetes and elevated cardiovascular risk.1 Using data from the same study programme, the authors have assessed the effect of canagliflozin among patients with and without a history of cardiovascular disease (secondary versus primary prevention).2
The study involved two trials that randomly assigned 10,142 participants with type 2 diabetes to canagliflozin or placebo.1, 2 …